Health and Fitness Health and Fitness
Thu, August 5, 2010
[ Thu, Aug 05th 2010 ] - Market Wire
MannKind to Present at the 30th Annual Canaccord Genuity Growth Conference
[ Thu, Aug 05th 2010 ] - Market Wire
Ramius Highlights Concerns Regarding Recent Trans .. otion With Forest Laboratories Without First Expl
[ Thu, Aug 05th 2010 ] - Market Wire
Media Advisory - Oncolytics Biotech(R) Inc. to Pr .. t 30th Annual Canaccord Genuity Growth Conference
[ Thu, Aug 05th 2010 ] - Market Wire
Aeterna Zentaris Announces NIH Grant for a Phase .. 2 Study in Advanced Prostate Cancer with AEZS-108
[ Thu, Aug 05th 2010 ] - Market Wire
YM BioSciences announces conclusion of Phase I do .. nsion of ongoing CYT387 Phase I/II clinical study
[ Thu, Aug 05th 2010 ] - Market Wire
Quidel to Present at Canaccord Genuity 30th Annual Growth Conference
[ Thu, Aug 05th 2010 ] - Market Wire
FDA Approves New Taxotere® (docetaxel) Injection Concentrate Formulation
Wed, August 4, 2010
[ Wed, Aug 04th 2010 ] - Market Wire
Somaxon Pharmaceuticals to Report Second Quarter .. d Conduct Conference Call on Wednesday, August 11
[ Wed, Aug 04th 2010 ] - Market Wire
ZIOPHARM Oncology to Present at the Canaccord Genuity 30th Annual Global Growth Conference
[ Wed, Aug 04th 2010 ] - Market Wire
Orthofix International to Participate in Canaccord Genuity Growth Conference
[ Wed, Aug 04th 2010 ] - Market Wire
Abiomed Reports Record U.S. Impella Utilization for First Quarter of Fiscal 2011
[ Wed, Aug 04th 2010 ] - Market Wire
Celldex Reports Second Quarter 2010 Financial Results
[ Wed, Aug 04th 2010 ] - Market Wire
Aeterna Zentaris to Announce Second Quarter 2010 .. inancial and Operating Results on August 12, 2010
[ Wed, Aug 04th 2010 ] - Market Wire
Lux Biosciences receives Complete Response letter from FDA for voclosporin
[ Wed, Aug 04th 2010 ] - Market Wire
Teleflex Prices Offering of $350 Million Convertible Senior Subordinated Notes Due 2017
[ Wed, Aug 04th 2010 ] - Market Wire
Concerned Osteotech Stockholders Announce Nominat .. bers to the Board of Directors of Osteotech, Inc.
[ Wed, Aug 04th 2010 ] - Market Wire
UnitedHealth Group Board Authorizes Payment of Quarterly Dividend to Shareholders
[ Wed, Aug 04th 2010 ] - Market Wire
Theragenics to Report Second Quarter 2010 Financial Results Tuesday, August 10
[ Wed, Aug 04th 2010 ] - Market Wire
Tenet Announces Pricing of Its Private Offering of Senior Notes due 2020
[ Wed, Aug 04th 2010 ] - Market Wire
ZymoGenetics to Webcast Presentation at the Canaccord Annual Growth Conference
Tue, August 3, 2010
[ Tue, Aug 03rd 2010 ] - Market Wire
Robbins Geller Rudman & Dowd LLP Files Class Action Suit against Almost Family, Inc.
[ Tue, Aug 03rd 2010 ] - Market Wire
Humana Military Healthcare Services Named in the .. for Military Times 2010 aBest Employers for Vetsa
[ Tue, Aug 03rd 2010 ] - Market Wire
Neurocrine Biosciences, Big 5 Sporting Goods, Aetna, CVS Caremark and Express Scripts
[ Tue, Aug 03rd 2010 ] - Market Wire
Humana, Unitedhealth, Allergan, Medicis Pharma and Johnson & Johnson
[ Tue, Aug 03rd 2010 ] - Market Wire
Enzon Reports Second Quarter 2010 Results
[ Tue, Aug 03rd 2010 ] - Market Wire
Five Prime Therapeutics, Inc. Announces Strategic .. e to Discover Innovative Biologics for Skeletal M
[ Tue, Aug 03rd 2010 ] - Market Wire
AMAG Pharmaceuticals, Inc. to Present at Canaccord Genuity 30th Annual Global Growth Conference
[ Tue, Aug 03rd 2010 ] - Market Wire
Array BioPharma to Report Financial Results for t .. er and Full Year of Fiscal 2010 on August 9, 2010
[ Tue, Aug 03rd 2010 ] - Market Wire
DexCom Inc. Reports Second Quarter 2010 Financial Results
[ Tue, Aug 03rd 2010 ] - Market Wire
ArQule en Daiichi Sankyo gaan door met fase-3 kli .. lan voor ARQ 197 bij niet-kleincellige longkanker

ArQule en Daiichi Sankyo gaan door met fase-3 klinisch onderzoeksplan voor ARQ 197 bij niet-kleincellige longkanker


Published on 2010-08-03 13:36:08 - Market Wire
  Print publication without navigation


WOBURN, Mass. and TOKYO--([ BUSINESS WIRE ])--ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC). In connection with this decision, the sponsor company, Daiichi Sankyo, will file a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for a trial comparing ARQ 197 plus erlotinib against erlotinib plus placebo.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.

Contributing Sources